Slideshow
Author(s):
These medical apps provided technology for caregivers to track symptoms, make appointments with doctors, monitor medications, and more.
Insights From the TRAILBLAZER-ALZ Program: Elevated ARIA Risk with Donanemab Highlights the Need for Vigilant Monitoring
Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
Blueprints for Better Care: 2024 Neurology Guideline Highlights
Neurology Unwrapped: 2024’s Most Intriguing Conversations
EU’s CHMP Reaffirms Positive Opinion of Alzheimer Treatment Lecanemab
FDA Closes Inspection of Site for Phase 3 TRANQUILITY II Trial of BXCL501 in Alzheimer Agitation